WallStSmart

Quipt Home Medical Corp (QIPT)vsRaytheon Technologies Corp (RTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Raytheon Technologies Corp generates 33338% more annual revenue ($88.60B vs $264.97M). RTX leads profitability with a 7.6% profit margin vs -4.0%. RTX earns a higher WallStSmart Score of 55/100 (C-).

QIPT

Hold

40

out of 100

Grade: D

Growth: 7.3Profit: 2.5Value: 5.0Quality: 5.0

RTX

Buy

55

out of 100

Grade: C-

Growth: 6.0Profit: 5.5Value: 4.7Quality: 7.0
Piotroski: 6/9Altman Z: 1.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for QIPT.

RTXSignificantly Overvalued (-95.4%)

Margin of Safety

-95.4%

Fair Value

$99.80

Current Price

$195.00

$95.20 premium

UndervaluedFair: $99.80Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

QIPT2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
32.0%10/10

Revenue surging 32.0% year-over-year

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

RTX2 strengths · Avg: 9.0/10
Market CapQuality
$261.12B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$3.19B8/10

Generating 3.2B in free cash flow

Areas to Watch

QIPT4 concerns · Avg: 2.5/10
Market CapQuality
$162.30M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
1.5%3/10

Operating margin of 1.5%

Return on EquityProfitability
-9.3%2/10

ROE of -9.3% — below average capital efficiency

EPS GrowthGrowth
-97.7%2/10

Earnings declined 97.7%

RTX4 concerns · Avg: 3.3/10
P/E RatioValuation
39.0x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.554/10

Distress zone — elevated risk

Profit MarginProfitability
7.6%3/10

7.6% margin — thin

PEG RatioValuation
2.782/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : QIPT

The strongest argument for QIPT centers on Revenue Growth, Price/Book. Revenue growth of 32.0% demonstrates continued momentum.

Bull Case : RTX

The strongest argument for RTX centers on Market Cap, Free Cash Flow. Revenue growth of 12.1% demonstrates continued momentum.

Bear Case : QIPT

The primary concerns for QIPT are Market Cap, Operating Margin, Return on Equity.

Bear Case : RTX

The primary concerns for RTX are P/E Ratio, Altman Z-Score, Profit Margin.

Key Dynamics to Monitor

QIPT profiles as a hypergrowth stock while RTX is a value play — different risk/reward profiles.

QIPT carries more volatility with a beta of 0.49 — expect wider price swings.

QIPT is growing revenue faster at 32.0% — sustainability is the question.

RTX generates stronger free cash flow (3.2B), providing more financial flexibility.

Bottom Line

RTX scores higher overall (55/100 vs 40/100) and 12.1% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Quipt Home Medical Corp

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Quipt Home Medical Corp. The company is headquartered in Wilder, Kentucky.

Raytheon Technologies Corp

INDUSTRIALS · AEROSPACE & DEFENSE · USA

Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization. Raytheon Technologies (RTX) researches, develops, and manufactures advanced technology products in the aerospace and defense industry, including aircraft engines, avionics, aerostructures, cybersecurity, guided missiles, air defense systems, satellites, and drones.

Visit Website →

Want to dig deeper into these stocks?